

Patient Characteristics in the Pivotal Phase 3 PEACE Trial of Pegzilarginase Human Enzyme Therapy for Arginase 1 Deficiency

Gregory M. Enns, MB, ChB¹; Rossana Sanchez Russo, MD²; Gillian Bubb, PhD³;
Eric Bradford, MD, MSc, MBA³; Serena Gasperini, MD⁴; George A. Diaz, MD, PhD⁵

¹Stanford University School of Medicine, Stanford, California, United States; ²Emory University School of Medicine, Atlanta, Georgia, United States; ³Aeglea BioTherapeutics, Inc., Austin, Texas, United States; ⁴Paediatric Department, Fondazione MBBM, Monza, Italy; ⁵Icahn School of Medicine at Mount Sinai, New York City, New York, United States


Acknowledgments: The authors thank the PEACE trial patients and their families.

Disclosures: The PEACE study and medical writing support are sponsored by Aeglea. **GME** and **GAD** have served on advisory boards for Aeglea. **GME**, **RSR**, **SG**, and **GAD** are PEACE investigators. **GB** and **EB** are employees of Aeglea.

ARG1-D Disease Background

- Arginase 1 Deficiency (ARG1-D) is a rare, debilitating inherited metabolic disorder caused by mutations in the *ARG1* gene and characterized by a marked reduction in arginase 1 activity that leads to significant accumulation of arginine^{1,2}
- Affected patients demonstrate a distinct, progressive neurologic phenotype with prominent lower-limb spasticity that leads to impaired mobility including difficulties in walking and climbing stairs; patients may ultimately become reliant on assistive devices^{1,3-5} (**Figure 1**)
- Current disease management includes dietary protein restriction to minimize arginine intake and, in some patients, nitrogen scavengers to reduce the risk of hyperammonemia
- Dietary protein restriction is largely inadequate to sufficiently reduce arginine levels and prevent progression
 - The normal plasma arginine range is estimated to be 40–115 $\mu\text{mol/L}$ based on analysis of data from the Framingham cohort⁶
 - Current guidelines for managing ARG1-D recommend reducing plasma arginine to $\leq 200 \mu\text{mol/L}$ ³
 - In an analysis of Urea Cycle Disorder Consortium data (22 patients with 1–13 data points per patient), <10% of plasma arginine assessments were $\leq 200 \mu\text{mol/L}$ ⁷

Figure 1. ARG1-D Disease Progression



1. Diez-Fernandez C, et al. *Hum Mutat.* 2018;39(8):1029-1050. 2. Sun A, et al. Arginase deficiency. *GeneReviews*® [Internet]. 2004 [Updated 2020]. 3. Häberle J, et al. *J Inherit Metab Dis.* 2019;42(6):1192-1230. 4. Carvalho DR, et al. *Pediatr Neurol.* 2012;46(6):369-374. 5. Huemer M, et al. *J Inherit Metab Dis.* 2016;39(3):331-340. 6. Luneburg N, et al. *J Nutr.* 2011;141(12): 2186-2190. 7. Burrage LC, et al. *Hum Mol Genet.* 2015;24(22):6417-6427.

Pegzilarginase and Insights from a Phase 1/2 Clinical Trial (Study 102A)

Pegzilarginase

- Pegzilarginase is an investigational arginine-lowering recombinant human enzyme therapy with 20-fold greater catalytic activity and a 10-fold longer half life than wild-type arginase^{8,9}


Study Design

- Study 102A was a Phase 1/2 open-label trial in 14 patients with ARG1-D¹⁰
- Patients received weekly pegzilarginase treatment administered by intravenous infusion with an option to switch to subcutaneous injection after 24 doses¹⁰

Control of Plasma Arginine

- Marked elevation of plasma arginine levels at baseline was consistent with published observations on the failure of standard-of-care treatment to adequately lower arginine¹⁰
- Pegzilarginase treatment resulted in rapid, substantial, and sustained reductions in plasma arginine levels^{10,11} (**Figure 2**)
- Meaningful and durable improvements in mobility assessments were achieved in 79% of patients at week 20 and were sustained through week 56^{10,11}

Figure 2. Plasma Arginine Control With Pegzilarginase¹¹



Potential Utility of Clinical Outcome Assessments of Mobility in Capturing Disease Burden and Clinical Impact of Lowering Plasma Arginine

- Study 102A provided the first important insights into the potential utility of clinical outcome assessments of mobility in patients with ARG1-D
 - Plasma arginine reductions were accompanied by meaningful mobility improvements
 - The Gross Motor Function Measure part E (GMFM-E; unaided walking, running, jumping tasks) and 6-minute walk test (6MWT; aided timed walk test) provided complementary insights about patients' baseline mobility impairments and pegzilarginase-related mobility improvements
 - GMFM-E was effective in capturing improvement in mobility. Patients with less severe impairment at baseline (and therefore higher baseline scores) demonstrated smaller improvements due to a ceiling effect
 - The 6MWT was also useful in capturing mobility improvements, particularly in patients who were at or close to the ceiling of GMFM-E

PEACE Trial Design

- The Phase 3 PEACE trial (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints, NCT03921541) is a pivotal randomized, double-blind, placebo-controlled study of weekly pegzilarginase treatment added to standard-of-care management (**Figure 3**)

- Key eligibility criteria were: documented diagnosis of ARG1-D and high baseline arginine (on standard of care; **Table 1**)

- Dosing of the first patient occurred in June 2019 and patient randomization was completed in Q2 2021

- Key efficacy endpoints are:
 - Primary: plasma arginine reduction
 - Key secondary: GMFM-E and 2MWT*

Figure 3. PEACE Trial Design




Table 1. Patient Eligibility Criteria

Inclusion
<ul style="list-style-type: none"> Documented ARG1-D diagnosis with ≥ 1 of the following: <ul style="list-style-type: none"> Elevated plasma arginine Pathogenic ARG1 variant Diminished erythrocyte arginase activity Baseline plasma arginine $\geq 250 \mu\text{mol/L}$ Age ≥ 2 years Baseline impairment in ≥ 1 clinical response assessment
Exclusion
<ul style="list-style-type: none"> Symptomatic hyperammonemia (ammonia $\geq 100 \mu\text{mol/L}$ and requiring acute care or hospitalization) ≤ 6 w before first dose of pegzilarginase Extreme mobility impairment (inability to complete assessments) Participation in a prior pegzilarginase study Prior liver or hematopoietic transplant

2MWT, 2-minute walk test; GMFM-E, Gross Motor Function Measure part E; IV, intravenous; SC, subcutaneous; w, weeks.

*Due to its shorter duration, the 2MWT was used to avoid a potential confounding effect of distraction owing to age and/or intellectual disability.

PEACE Baseline Characteristics

- A total of 44 patients were screened; 32 patients were randomized to treatment (**Table 2**), exceeding the target enrollment of 30
- Median plasma arginine was 407 $\mu\text{mol/L}$, which is similar to levels observed in the Phase 1/2 study (median, 389 $\mu\text{mol/L}$)¹⁰
- All patients were managed with a restricted protein diet; a large proportion were receiving EAA supplementation
- Only 25% of patients were identified by newborn screening


Table 2. PEACE Patient Demographics and Baseline Disease Characteristics

Characteristic	Value (N=32)
Age at enrollment, y	
Mean \pm SD	11 \pm 6.5
Range	2–29
Sex, n (%)	
Male	19 (59)
Female	13 (41)
Management approach, n (%)	
Restricted protein diet	32 (100)
EAA supplementation	27 (84)
Nitrogen scavenger therapy	23 (72)
Restricted protein diet, EAA supplementation, and nitrogen scavenger therapy	19 (59)
Plasma arginine, $\mu\text{mol/L}$	
Median	407.3
Range	230–617
Age at onset of manifestations, y	
Mean \pm SD	2 \pm 2.5
Range	0–10
Key medical history, n (%)	
Spasticity	21 (66)
Moderate-to-severe	12 (38)
Hyperammonemia history	17 (53)
Seizure history	11 (34)

Baseline Functional Impairment

- The Gross Motor Function Classification System (GMFCS; **Figure 5**) was originally developed for cerebral palsy, which, like ARG1-D, is characterized by impaired mobility due to spasticity
- GMFCS evaluates self-initiated movement with emphasis on sitting, walking, ascending stairs, and wheeled mobility
 - Level 1 indicates ability to walk, climb stairs without use of a railing, and perform gross motor skills (eg, running, jumping), but with limited speed, balance, and coordination
 - Levels ≥ 2 indicate progressively greater mobility impairment and reliance on assistive devices
- In PEACE, 41% of patients (n=13) were classified as GMFCS Level 1 and 56% (n=18) were GMFCS ≥ 2 (indicating more significant functional impairment)*
 - More patients in PEACE were classified as GMFCS ≥ 2 than in the Phase 1/2 study (46%)¹⁰
 - No patients at GMFCS Level 5 were enrolled

Figure 5. **GMFCS Scoring**^{12,13}




Adapted with permission from The Royal Children's Hospital, Melbourne, Australia.

10. Diaz GA, et al. *J Inherit Metab Dis*. 2020;doi:10.1002/jimd.12343. 12. Palisano R, et al. *Dev Med Child Neurol*. 1997;39(4):214-223. 13. The Royal Children's Hospital, Melbourne, Australia. GMFCS Descriptors and Illustrations. Accessed October 13, 2021.

*Baseline GMFCS score is missing for 1 patient.

Baseline Mobility Impairment

- The GMFM is an instrument designed to evaluate motor function, including changes over time and/or with intervention. Notably, the GMFM is performed without any needed bracing or assistive devices
- GMFM-E evaluates 24 tasks involving walking forward/backward, running, jumping, and ascending/descending stairs. Possible scores range from 0–72, with lower scores indicating greater impairment
 - Median score was 54 points
 - 84% of patients demonstrated a mobility deficit on GMFM-E, defined as a score of <68 points. In comparison, 56% of patients were classified as having a GMFM-E deficit in Study 102A¹⁰
 - As expected, patients at GMFCS ≥ 2 demonstrated lower baseline GMFM-E scores compared with patients at GMFCS =1 (41 vs 67 points)
- 72% of patients demonstrated baseline impairment on the supportive GMFM part D (GMFM-D; standing, balancing, squatting, transitioning from sitting to standing). Median score was 31 of a possible 39 points; deficit was defined as a score <35 points
- The 2MWT evaluates aided mobility, through distance traveled in 2 minutes with any needed bracing or assistive devices
 - 84% of patients demonstrated a mobility deficit on the 2MWT, defined using age- and sex-based criteria from the NIH Toolbox dataset. In comparison, 88% of patients in Study 102A had a deficit on the 6MWT¹⁰
 - Median distance traveled was 118 meters; in comparison, the median 6MWT distance traveled in 102A was 272 meters
 - Patients at GMFCS ≥ 2 demonstrated a reduced baseline distance compared with those at GMFCS =1 (81 vs 150 meters)



Assessment*	GMFM-E (points)	2MWT (meters)
Percent impaired	84%	84%
Median score (range)	54 (0–72)	119 (0–202)

*Data have been updated to include a patient without available data at the time of abstract development. Each GMFM task is scored as: 0 (does not initiate), 1 (initiates), 2 (partially completes), 3 (completes), or NT (not tested; no score).

Summary and Conclusions

- The Phase 3 PEACE study is the first randomized placebo-controlled clinical trial in ARG1-D
- Baseline characteristics of PEACE study participants provide important demographic and disease insights in a well-studied cohort of 32 ARG1-D patients and are consistent with information provided by the previous Phase 1/2 trial cohort. These patients appear to be representative of the broader ARG1-D population
- Baseline plasma arginine measurements on current standard of care are markedly elevated
 - The observed median arginine level of >400 $\mu\text{mol/L}$ clearly demonstrates the inadequacy of standard-of-care management in reducing arginine to prevent disease progression and functional impairment
- The PEACE cohort provides further evidence of the utility of GMFM-E and timed walk test in capturing disease burden and providing complementary insights on the impact of ARG1-D on mobility
- Top-line PEACE data are anticipated in Q4 2021

Thank You

- We thank the PEACE investigators, support staff, patients, and caregivers
- Contact information
 - **Dr George Diaz**
Professor, Division of Medical Genetics, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai
Director, Program for Inherited Metabolic Diseases
george.diaz@mssm.edu
 - **Dr Mark Bechter**
Vice President, Medical Affairs, Aeglea BioTherapeutics
mbechter@aeglea.com
- Related ARG1-D posters
 - **62:** Diagnosis and Long-term Management of Arginase 1 Deficiency
 - **63:** Diagnosis of Arginase 1 Deficiency In a Patient With Cerebral Palsy
 - **65:** Gait Improvement in Pegzilarginase-treated Patients with Arginase 1 Deficiency: A Blinded Kinematic Analysis
 - **116:** Arginase 1 Deficiency Presenting with Clotting Abnormalities
 - **118:** Arginine: The Key Driver of Pathophysiology and Progression in Arginase 1 Deficiency
 - **126:** Management and Progression of Arginase 1 Deficiency Over 2 Decades of Follow-up
- For more information: aeglea.com